UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

European journal of cancer (1990), 2020-10, Vol.138, p.S1-S2

2020

Link zum Volltext

Verfügbarkeit prüfen

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

European journal of cancer (1990), 2015-09, Vol.51, p.S107-S108

2015

Link zum Volltext

Verfügbarkeit prüfen

Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S6-S7

2014

Link zum Volltext

Verfügbarkeit prüfen

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S43-S44

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S34-S34

2014

Link zum Volltext

Verfügbarkeit prüfen

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1700-1709

2015

Link zum Volltext

Verfügbarkeit prüfen

A Single Nucleotide Polymorphism in the MTHFR Gene is Associated with Risk of Treatment-Related Pneumonitis in Lung Cancer Patients Treated with Thoracic Radiation Therapy

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S573-S574

2011

Link zum Volltext

Verfügbarkeit prüfen

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Annals of oncology, 2011-12, Vol.22 (12), p.2616-2624

2011

Link zum Volltext

Verfügbarkeit prüfen

Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study

European journal of cancer (1990), 2022-10, Vol.174, p.S21-S21

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met

Annals of oncology, 2019-10, Vol.30, p.v596-v597

2019

Link zum Volltext

Verfügbarkeit prüfen

1469P - Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met

Annals of oncology, 2019-10, Vol.30, p.v596-v597

2019

Link zum Volltext

Verfügbarkeit prüfen

1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial

Annals of oncology, 2021-09, Vol.32, p.S986-S987

2021

Link zum Volltext

Verfügbarkeit prüfen

MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S118

2023

Link zum Volltext

Verfügbarkeit prüfen

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S175

2023

Link zum Volltext

Verfügbarkeit prüfen

1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC

Annals of oncology, 2020-09, Vol.31, p.S881-S882

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Annals of oncology, 2021-09, Vol.32, p.S1326-S1327

2021

Link zum Volltext

Verfügbarkeit prüfen

1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study

Annals of oncology, 2020-09, Vol.31, p.S830-S830

2020

Link zum Volltext

Verfügbarkeit prüfen

B11 Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.S30-S31

2020

Link zum Volltext

Verfügbarkeit prüfen

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S751-S752

2021

Link zum Volltext

Verfügbarkeit prüfen

MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S24-S25

2021

Link zum Volltext

Verfügbarkeit prüfen

447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v164-v164

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v164

2019

Link zum Volltext

Verfügbarkeit prüfen

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii741-viii742

2018

Link zum Volltext

Verfügbarkeit prüfen

Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii133

2018

Link zum Volltext

Verfügbarkeit prüfen

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii496-viii497

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(5)
Oncology
(4)
Radiology
(4)
Aged
(3)
Female
(3)
Humans
(3)
Life Sciences & Biomedicine
(3)
Lung Neoplasms - Drug Therapy
(3)
Male
(3)
Middle Aged
(3)
Mutation
(3)
Science & Technology
(3)
Adult
(2)
Antineoplastic Agents
(2)
Biological And Medical Sciences
(2)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(2)
Carcinoma, Non-Small-Cell Lung - Genetics
(2)
Care And Treatment
(2)
Clinical Trials
(2)
Lung Cancer
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(27)
Journals@Ovid Complete
(27)
Ingenta
(14)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(10)
Elsevier ScienceDirect Journals Complete
(10)
IngentaConnect Journals
(6)
MEDLINE
(3)
Publisher site
(2)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

A Single Nucleotide Polymorphism in the MTHFR Gene is Associated with Risk of Treatment-Related Pneumonitis in Lung Cancer Patients Treated with Thoracic Radiation Therapy

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study

Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met

1469P - Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met

1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial

MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC

MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study

B11 Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy

447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Suchergebnisse filtern